Article
Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotype.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association - 1 Feb 2013
Carroll Robert P, Hester Joanna, Wood Kathryn J, Harden Paul N
Abstract excerpt
BACKGROUND: Conversion to sirolimus from calcineurin inhibitor- (CNI), azathioprine- (AZA) and mycophenolate-based regimens reduces the risk of development of squamous cell carcinoma of the skin (SCC) in kidney transplant recipients (KTRs). Sirolimus conversion may also be protective by permitting beneficial changes in immune phenotype. It is not known how sirolimus will affect immune phenotype in KTRs with SCC....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.